share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股sec公告 ·  05/21 13:05
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Herzliya, Israel, seeks to have the registration become effective on May 22, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. NeuroSense Therapeutics has authorized its counsel, Greenberg Traurig, P.A., and specifically Gary Emmanuel, to communicate with the SEC regarding the effectiveness of the Registration Statement and to modify or withdraw the request for acceleration if necessary.
NeuroSense Therapeutics Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Herzliya, Israel, seeks to have the registration become effective on May 22, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. NeuroSense Therapeutics has authorized its counsel, Greenberg Traurig, P.A., and specifically Gary Emmanuel, to communicate with the SEC regarding the effectiveness of the Registration Statement and to modify or withdraw the request for acceleration if necessary.
神经感知治疗有限公司(NeuroSense Therapeutics Ltd.)是一家生物制药公司,正式要求证券交易委员会(SEC)加快其F-1表格的注册声明有效性。该公司位于以色列赫尔兹利亚,希望在2024年5月22日美国东部时间下午4:00左右,该注册声明生效。该要求是根据1933年修正的证券法案的规则461作出的。 NeuroSense Therapeutics已授权其律师Greenberg Traurig,PA以及特别是Gary Emmanuel与SEC就注册声明的有效性进行沟通,并在必要时修改或撤回加速要求。
神经感知治疗有限公司(NeuroSense Therapeutics Ltd.)是一家生物制药公司,正式要求证券交易委员会(SEC)加快其F-1表格的注册声明有效性。该公司位于以色列赫尔兹利亚,希望在2024年5月22日美国东部时间下午4:00左右,该注册声明生效。该要求是根据1933年修正的证券法案的规则461作出的。 NeuroSense Therapeutics已授权其律师Greenberg Traurig,PA以及特别是Gary Emmanuel与SEC就注册声明的有效性进行沟通,并在必要时修改或撤回加速要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息